Epizootic hemorrhagic disease vaccine
Inventors
Richt, Juergen A. • Morozov, Igor • Sunwoo, Sun Young • Wilson, William C.
Assignees
United States, As Reoresented By Secretary Of Agriculture • Kansas State University • US Department of Agriculture USDA
Publication Number
US-10881722-B2
Publication Date
2021-01-05
Expiration Date
2037-09-18
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides for an immunogenic composition against epizootic hemorrhagic disease virus (EHDV). The immunogenic composition has been shown to be efficacious in inducing serum neutralizing antibodies against EHDV and intended to be used to prevent or reduce clinical symptoms associated with EHDV infection in susceptible animals. The disclosure provides for composition and methods that represent an improvement over previous strategies for treating and preventing EHDV.
Core Innovation
The invention provides an immunogenic composition or vaccine against epizootic hemorrhagic disease virus (EHDV). The composition is designed to induce serum neutralizing antibodies against EHDV and can be administered to susceptible animals to prevent or reduce clinical symptoms of EHDV infection. The vaccine comprises protein subunits or DNA-based components, preferably utilizing VP2 and VP5 structural proteins from one or multiple EHDV serotypes, produced recombinantly, such as via a baculovirus expression system.
The immunogenic composition offers advantages over traditional autogenous inactivated vaccines, such as not requiring live virus propagation and inactivation, allowing faster production, and enabling differentiation of infected from vaccinated animals (DIVA compatibility). This composition can reduce the incidence and severity of clinical signs including loss of appetite, fever, lameness, hemorrhages, and death in animals susceptible to EHD.
Claims Coverage
The claims disclose four main inventive features related to immunogenic compositions comprising VP2 subunits and methods of using them to reduce symptoms of EHD.
Immunogenic composition comprising at least two VP2 subunits from different EHDV serotypes
An immunogenic composition comprising at least two VP2 subunits from different serotypes of EHDV along with at least one component selected from antigens, pharmaceutical carriers, adjuvants, preservatives, stabilizers, or combinations thereof.
Use of baculovirus expression system for producing VP2 subunit proteins
The VP2 subunits in the immunogenic composition are proteins expressed using a baculovirus expression system, enabling recombinant production of the vaccine components.
Administration methods to reduce incidence or severity of EHD clinical symptoms
Methods of reducing at least one clinical symptom of EHD by administering the immunogenic composition with at least two VP2 subunits and additional components, targeting symptoms such as loss of appetite, fever, salivation, lameness, and death.
Administration methods to reduce symptoms of subclinical EHD
Methods of reducing incidence or severity of at least one clinical symptom associated with subclinical EHD by administering an immunogenic composition comprising at least two VP2 subunits and components such as carriers or adjuvants, targeting symptoms including viremia, fever, oral ulcers, salivation, lameness, and coronitis.
The claims focus on compositions comprising multiple VP2 subunits from different EHDV serotypes produced via baculovirus systems, and methods of using these compositions to alleviate clinical and subclinical symptoms of EHD in animals by administering them, optionally including various vaccine formulation components.
Stated Advantages
The use of recombinant protein vaccines, particularly VP2 and VP5 subunits, which are safe and protective compared to whole inactivated virus vaccines.
Avoidance of live virus propagation and virus inactivation steps, resulting in faster and safer vaccine production.
DIVA compatibility allowing differentiation between vaccinated and infected animals, aiding disease control.
Ability to induce neutralizing antibodies and cross-reactive immunity against multiple EHDV serotypes through inclusion of VP2 and VP5 from different serotypes.
Documented Applications
Preventing or reducing clinical symptoms of epizootic hemorrhagic disease in susceptible animals such as cattle and white-tailed deer.
Reducing incidence and severity of subclinical EHDV infections characterized by viremia, virus shedding, mild fever, and loss of appetite.
Reducing viremia levels in EHDV-infected animals to control disease spread.
Interested in licensing this patent?